Present and future of breast cancer anti-Her-2-therapy
The paper describes a new class of molecular targeted antitumor agents against the molecules involved in carcinogenesis. It considers the basic drugs of this class and their combinations and evaluates the efficiency of their use in therapy for breast cancer.
Saved in:
Main Author: | V. P. Letyagin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-07-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/160 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer
by: Gavin P. Dowling, et al.
Published: (2025-05-01) -
Silver Jubilee of HER2 targeting: a clinical success in breast cancer
by: Jianli Zhao, et al.
Published: (2025-08-01) -
POSSIBILITIES OF THERAPY OF HER-2-POSITIVE REGIONAL BREAST CANCER
by: A. S. Belokhvostova, et al.
Published: (2015-04-01) -
Current research status on HER2 protein expression levels and the efficacy of targeted therapy in breast cancer
by: Jiani Liu, et al.
Published: (2025-06-01) -
HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01)